|
|
Volumn 10, Issue 11, 2011, Pages 797-798
|
|
Accelerated approval dust begins to settle
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BEVACIZUMAB;
BRENTUXIMAB VEDOTIN;
CARFILZOMIB;
CRIZOTINIB;
EC 145;
GANETESPIB;
NILOTINIB;
PONATINIB;
TRASTUZUMAB;
UNCLASSIFIED DRUG;
VISMODEGIB;
ADVANCED CANCER;
ARTICLE;
BASAL CELL CARCINOMA;
BREAST CANCER;
DRUG APPROVAL;
DRUG INDUSTRY;
DRUG RESEARCH;
DRUG RESPONSE;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
LUNG NON SMALL CELL CANCER;
MULTIPLE MYELOMA;
PRIORITY JOURNAL;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS AS TOPIC;
DRUG APPROVAL;
DRUG DISCOVERY;
HUMANS;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 80155150453
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd3580 Document Type: Article |
|
Times cited : (3)
|
|
References (0)
|
